The present disclosure relates to novel and advantageous heart valves formed from a biomaterial.
The background description provided herein is for the purpose of generally presenting the context of the disclosure. Work of the presently named inventors, to the extent it is described in this background section, as well as aspects of the description that may not otherwise qualify as prior art at the time of filing, are neither expressly nor impliedly admitted as prior art against the present disclosure.
Native heart valves may need to be replaced when a patient has a condition such as congenital heart defect or valvular heart disease. A diseased heart valve may result in regurgitation, where the valve is not properly function and blood flows in a direction opposite the normal direction of the flow, and/or stenosis, where the valve has narrowed through in some instances calcification of the valve, some obstruction of the valve such as plaque, or inflammation. Heart valves may be replaced through surgical repair or a valve deployed relative to the native heart valve through a transcatheter approach. Transcatheter valve replacement devices generally comprise leaflets of tissue that are attached to an expandable or self-expanding stent construct that is crimped onto a catheter for deployment. The stent is advanced to the location of the troubled heart valve, where it expands or is expanded by a balloon or other means. Once seated in the valve, blood flow and the muscles of the heart will result in the tissue leaflets to open and close. When manufacturing these transcatheter valve replacement devices, one of the most time-consuming and labor-intensive portions of the process is attaching the leaflets securely to the stent. The leaflets are attached to the stent with hundreds of sutures, generally hand sewn by a skilled laborer. Often each valve replacement devices may have anywhere from 150 sutures to 300 sutures or more. To reduce the cost and time needed to manufacture these devices, it would be desirable to significantly reduce the number of sutures needed to securely attach the tissue to an expandable or self-expanding stent.
The following presents a simplified summary of one or more embodiments of the present disclosure in order to provide a basic understanding of such embodiments. This summary is not an extensive overview of all contemplated embodiments, and is intended to neither identify key or critical elements of all embodiments, nor delineate the scope of any or all embodiments.
In some embodiments, a heart valve replacement device of the present disclosure comprises a stent having a first end, a second end, an outer surface, and an inner surface, the inner surface defining a lumen; and a valve disposed within the lumen of the stent, the valve formed from a single sheet of tissue, the valve having an outer surface, an inner surface, and a thickness between the outer surface and the inner surface, the valve comprising at least three leaflets, wherein, the valve is attached to the stent with fewer than forty sutures. In some embodiments, the valve is attached to the stent with fewer than thirty sutures. In some embodiments, the valve is attached to the stent with fewer than twenty sutures. In some embodiments, the valve is attached to the stent with between three sutures and twenty sutures. In some embodiments of the present disclosure, the valve has a body portion connected to the leaflets. In at least one embodiment, the thickness of the body portion is different than the thickness of the leaflets. In some embodiments, the valve has a cuff portion, which may be connected to a body portion of the valve. In at least one embodiment, the thickness of the cuff portion is different than the thickness of the body portion. In at least one embodiment, the thickness of the cuff portion is different than the thickness of the leaflets. In at least one embodiment, the cuff portion that is expandable from a first position to a second position relative to the stent. The stent of the heart valve replacement device may have at least one attachment feature. In some embodiments, at least one suture connects the stent to the valve at the one attachment feature.
In some embodiments of the present disclosure, a replacement heart valve comprises a plurality of leaflets; and a body portion connected to the leaflets, wherein the body portion and the leaflets are formed from a single sheet of a tissue material. The replacement heart valve may comprise a cuff portion connected to the body portion. In some embodiments, the thickness of the leaflets may be different than the thickness of the cuff portion. In some embodiments, the thickness of the body portion may be different than the thickness of the cuff portion. In some embodiments, the tissue material is a biomaterial. In some embodiment, the valve comprises attachment points on at least the body portion of the heart valve.
In some embodiments, a method of manufacturing a replacement heart valve device, comprises forming a valve from a single sheet of tissue material, the valve having a body portion with at least three leaflets connected to the body portion; inserting the valve formed from a single sheet of material into a lumen of a stent; and securing the valve to the stent with fewer than forty sutures. In some embodiments, the valve is secured to the stent with fewer than thirty sutures. In some embodiments, the valve is secured to the stent with fewer than twenty sutures. In some embodiments, the valve is secured to the stent with between three and twenty sutures. In some embodiments, the step of forming the valve comprises inserting the single sheet of tissue material into a mold. The mold may have a lower portion (primary mold) and an upper portion (secondary mold). In some embodiments, the mold has a locking member for locking the upper position relative to the lower portion. In some embodiments, a spacer is inserted between the single sheet of tissue material and at least one of the upper portion and the lower portion. In some embodiments, a cross-linking process is applied to the single sheet of tissue material while in the mold. The tissue material may be an artificial tissue in some embodiments or a bio-material. In some embodiments, the single sheet of tissue material has varying thickness from one end of the material to the other. In some embodiments, the single sheet of material was cut from one end of the material to the other with a cutting device to vary the thickness from one end of the material to the other.
While multiple embodiments are disclosed, still other embodiments of the present disclosure will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. As will be realized, the various embodiments of the present disclosure are capable of modifications in various obvious aspects, all without departing from the spirit and scope of the present disclosure. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
While the specification concludes with claims particularly pointing out and distinctly claiming the subject matter that is regarded as forming the various embodiments of the present disclosure, it is believed that the invention will be better understood from the following description taken in conjunction with the accompanying Figures, in which:
The present disclosure relates to replacement heart valves for use in the mitral valve, tricuspid valve, aortic valve or pulmonary valve of the heart. In some circumstances, a replacement heart valve may be disposed within the native valve such that portions of the replacement heart valve, or portions of a device such as a stent attached to the replacement heart valve, are adjacent to the native heart valve.
In the following detailed description, numerous specific details are set forth in order to provide a thorough understanding of some embodiments. However, it will be understood by persons of ordinary skill in the art that some embodiments may be practiced without these specific details. In other instances, well-known methods, procedures, components, units and/or circuits have not been described in detail so as not to obscure the discussion.
The valve 108 may be attached to the stent with sutures or with other mechanical means at one or more attachment features 115. The valve 108 may also be attached to the stent 102 with an adhesive. The valve 108 may be attached to the stent 102 with the adhesive at the attachment features. The valve 108 may also be attached to the stent 102 with a polymer attachment layer. The valve 108, in some embodiments, may be attached with one or more of sutures, other mechanical attachment means, adhesive, or the polymer attachment layer.
The valve 108 may be constructed, in some embodiments, from a single piece of tissue material. In some embodiments, the tissue material may be a biomaterial. In some embodiments, the tissue material may be a cross-linked collagen based-biomaterial that comprises acellular or cellular tissue selected from the group consisting of cardiovascular tissue, heart tissue, heart valve, aortic roots, aortic wall, aortic leaflets, pericardial tissue, connective tissue, dura mater, dermal tissue, vascular tissue, cartilage, pericardium, ligament, tendon, blood vessels, umbilical tissue, bone tissue, fasciae, and submucosal tissue and skin. In some embodiments, the tissue material is an implantable biomaterial such as the biomaterial described in the disclosure of U.S. Pat. No. 9,205,172, filed on Dec. 21, 2005 and entitled “Implantable Biomaterial and Method of Producing Same,” which is incorporated by reference herein in its entirety. In some embodiments, the tissue material may be artificial tissue. In some embodiments, the artificial tissue may comprise a single piece molded or formed polymer. In some embodiments, the artificial tissue may comprise polytetrafluoroethylene, polyethylene terephthalate, other polymers, and other polymer coatings.
The valve 108 may have a proximal end 116 and a distal end 118. The valve 108 may have an outer surface 122 and an inner surface 124, where the inner surface 124 defines a lumen 125. The valve 108 may have at least one leaflet 126. In some embodiments, the valve 108 comprises at least three leaflets 126 that are connected to one another. In some embodiments, the valve 108 may comprise three leaflets 126. In some embodiments, the valve 108 may comprise two leaflets 126. In some embodiments, the valve 108 may comprise four leaflets 126. In some embodiments, the valve 108 may comprise more than four leaflets 126. The leaflets 126 may each form cup-like concave portions 128. Thus, the leaflets 126 are not flat pieces of tissue, but rather formed into a curved shape. Studies such as the one published in an article entitled Flat or Curved Pericardial Aortic Valve Cusps: A Finite Element Study, authored by Khee Hiang Lim, Johanes Candral, Joon Hock Yeo and Carlos M. G. Duran, Journal of Heart Valve, Vol. 13, No. 5 (September 2004), which is incorporated by reference herein in its entirety, have demonstrated that three-dimensional leaflet cusps similar to those shown herein have about a 35% reduction in stresses over a flat piece of tissue. The leaflets 126 are positioned adjacent to one another at commissures 130. The valve 108 may further comprise a body portion 132 connected to at least the leaflets 126. In some embodiments, the body portion 132 may be positioned distally relative to the leaflets. In at least one embodiment, the valve 108 may have an annulus region 138 at the distal end 112. The annulus region 136 may be connected to the body portion 132. In some embodiments, the valve 108 may have a cuff portion 140 attached to the annulus region 138. The cuff portion 140 may have an outer surface 142 and an inner surface 144. The cuff portion 140 may extend proximally over at least part of the body portion 132. The cuff portion 140 may, in some embodiments, be expandable to form a seal against the native tissue. In some embodiments, the valve 108 may further comprise a first edge 146 and a second edge 147 that form a seam 148 that extends axially along the valve 108. In some embodiments, the seam 148 may be joined with some adhesive or other chemical process. In some embodiments, the first edge 146 and the second edge 147 may be joined across seam 148 by one suture. In some embodiments, the first edge 146 and the second edge 147 may be joined across seam 148 by a first suture near a proximal end of the seam 148 and a second suture near a distal end of the seam 148. In some embodiments, the first edge 146 and the second edge 147 may be joined across seam 148 by a first suture near a proximal end of the seam 148, a second suture near a distal end of the seam 148, and at least one suture between the first suture and the second suture. In other embodiments, the seam 148 may form a relatively small gap between the first edge 146 and a second edge 147 without compromising performance of the valve. In some embodiments, the leaflets 126 may have a thickness between the outer surface 122 and the inner surface 124 that is less than the thickness of the body region.
The valve 108 may be disposed relative to the stent 102 such that the outer surface 122 of at least part of the valve 108 abuts the inner surface 112 of the stent 102. As shown at least in
At least in part because the valve is formed from a single piece of material, the valve may be attached to the stent with minimal sutures. In some embodiments,
In some embodiments, a method for manufacturing a valve of the present disclosure may comprise inserting a sheet of tissue into a mold in order to form the leaflets and the cuff, and then, in some embodiments, forming the molded tissue into a circular ring.
The lower portion 1122 of the mold 1100 is shown in
The upper portion 1120 of the mold 1100 is shown in
In some embodiments, the mold may be formed from a metal, a polymer or a ceramic material. In some embodiments, the mold may be printed using additive manufacturing such that the mold could be individually created for a patient and form a valve specific to that patient.
In at least one embodiment, a sheet of tissue may be inserted into the mold 1100 between the lower portion 1122 and the upper portion 1124. The locking means 1123 may then be engaged so that the lower portion 1122 and the upper portion 1124 are fixed in a closed position. In at least one embodiment, where the sheet of tissue is formed from a biomaterial, a cross-linking solution glutaraldehyde may be applied to the sheet of tissue in order to facilitate cross-linking of the tissue. In some embodiments, the cross-linking solution comprises glutaraldehyde. In some embodiments, the cross-linking solution may be injected into the tissue, and in other embodiments the tissue may be soaked, immersed in, or penetrated with the cross-linking solution. In some embodiments, the glutaraldehyde may be injected into the tissue, and in other embodiments the tissue may be soaked, immersed in, or penetrated with glutaraldehyde. In at least one embodiment, the mold 1100 with the sheet of tissue inserted into the mold, may be immersed into the cross-linking solution, which may comprise glutaraldehyde. In at least one embodiment, the upper portion 1124 may be removed from the mold 1100 when the tissue is partially cross-linked and the tissue may be removed from the mold 1100 once it is fully cross-linked. In at least one embodiment, the upper portion 1124 is removed from the mold 1100 while the mold 1100 remains immersed in the cross-linking solution or glutaraldehyde. In at least one embodiment, a spacer or a spacing layer may be inserted between one of the lower portion 1122 and the upper portion 1124 before the glutaraldehyde is applied to the sheet of tissue.
In some embodiments, the valve may be constructed from a single sheet of material having varying thickness. In some embodiments, a method for manufacturing a sheet of tissue for the valve may comprise using a cutting system 1500 as shown in
As used herein, the terms “substantially” or “generally” refer to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result. For example, an object that is “substantially” or “generally” enclosed would mean that the object is either completely enclosed or nearly completely enclosed. The exact allowable degree of deviation from absolute completeness may in some cases depend on the specific context. However, generally speaking, the nearness of completion will be so as to have generally the same overall result as if absolute and total completion were obtained. The use of “substantially” or “generally” is equally applicable when used in a negative connotation to refer to the complete or near complete lack of an action, characteristic, property, state, structure, item, or result. For example, an element, combination, embodiment, or composition that is “substantially free of” or “generally free of” an ingredient or element may still actually contain such item as long as there is generally no measurable effect thereof.
As used herein any reference to “one embodiment” or “an embodiment” means that a particular element, feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. The appearances of the phrase “in one embodiment” in various places in the specification are not necessarily all referring to the same embodiment.
As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having” or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Further, unless expressly stated to the contrary, “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
In addition, use of the “a” or “an” are employed to describe elements and components of the embodiments herein. This is done merely for convenience and to give a general sense of the description. This description should be read to include one or at least one and the singular also includes the plural unless it is obvious that it is meant otherwise.
Still further, the figures depict preferred embodiments for purposes of illustration only. One skilled in the art will readily recognize from the discussion herein that alternative embodiments of the structures and methods illustrated herein may be employed without departing from the principles described herein.
Upon reading this disclosure, those skilled in the art will appreciate still additional alternative structural and functional designs for the devices described herein. Thus, while particular embodiments and applications have been illustrated and described, it is to be understood that the disclosed embodiments are not limited to the precise construction and components disclosed herein. Various modifications, changes and variations, which will be apparent to those skilled in the art, may be made in the arrangement, operation and details of the method and apparatus disclosed herein without departing from the spirit and scope defined in the appended claims.
While the systems and methods described herein have been described in reference to some exemplary embodiments, these embodiments are not limiting and are not necessarily exclusive of each other, and it is contemplated that particular features of various embodiments may be omitted or combined for use with features of other embodiments while remaining within the scope of the invention. Any feature of any embodiment described herein may be used in any embodiment and with any features of any other embodiment.
Number | Name | Date | Kind |
---|---|---|---|
4624822 | Arru | Nov 1986 | A |
5855601 | Bessler | Jan 1999 | A |
6491511 | Duran et al. | Dec 2002 | B1 |
6682559 | Myers | Jan 2004 | B2 |
7025780 | Gabbay | Apr 2006 | B2 |
7087079 | Navia et al. | Aug 2006 | B2 |
8778018 | Iobbi | Jul 2014 | B2 |
8992599 | Thubrikar et al. | Mar 2015 | B2 |
9011525 | Claiborne, III et al. | Apr 2015 | B2 |
9095430 | Cunanan et al. | Aug 2015 | B2 |
9192470 | Cai | Nov 2015 | B2 |
9205172 | Leonard Neethling et al. | Dec 2015 | B2 |
9259313 | Wheatley | Feb 2016 | B2 |
9301835 | Campbell et al. | Apr 2016 | B2 |
9554902 | Braido et al. | Jan 2017 | B2 |
9744037 | Kheradvar et al. | Aug 2017 | B2 |
9763780 | Morriss et al. | Sep 2017 | B2 |
11135059 | Hammer et al. | Oct 2021 | B2 |
11464635 | Reimer et al. | Oct 2022 | B2 |
20030069635 | Cartledge | Apr 2003 | A1 |
20050123582 | Sung | Jun 2005 | A1 |
20050137687 | Salahieh et al. | Jun 2005 | A1 |
20050203614 | Forster et al. | Sep 2005 | A1 |
20050240262 | White | Oct 2005 | A1 |
20060020327 | Lashinski | Jan 2006 | A1 |
20080288055 | Paul, Jr. | Nov 2008 | A1 |
20100049313 | Mon et al. | Feb 2010 | A1 |
20110066224 | White | Mar 2011 | A1 |
20110238167 | Dove et al. | Sep 2011 | A1 |
20120078356 | Fish et al. | Mar 2012 | A1 |
20120277855 | Lashinski et al. | Nov 2012 | A1 |
20130018458 | Yohanan et al. | Jan 2013 | A1 |
20130184811 | Rowe et al. | Jul 2013 | A1 |
20130197631 | Bruchman et al. | Aug 2013 | A1 |
20130204360 | Gainor | Aug 2013 | A1 |
20130310927 | Quintessenza | Nov 2013 | A1 |
20140005772 | Edelman | Jan 2014 | A1 |
20140031924 | Bruchman et al. | Jan 2014 | A1 |
20140107772 | Li et al. | Apr 2014 | A1 |
20140277417 | Schraut | Sep 2014 | A1 |
20140324160 | Benichou et al. | Oct 2014 | A1 |
20150134056 | Claiborne, III et al. | May 2015 | A1 |
20150142104 | Braido | May 2015 | A1 |
20150209141 | Braido et al. | Jul 2015 | A1 |
20150216663 | Braido et al. | Aug 2015 | A1 |
20150289973 | Braido et al. | Oct 2015 | A1 |
20150320556 | Levi et al. | Nov 2015 | A1 |
20160128831 | Zhou et al. | May 2016 | A1 |
20160135951 | Salahieh et al. | May 2016 | A1 |
20160143732 | Glimsdale | May 2016 | A1 |
20160158007 | Centola et al. | Jun 2016 | A1 |
20160175095 | Dienno et al. | Jun 2016 | A1 |
20160220365 | Backus et al. | Aug 2016 | A1 |
20160317293 | Matheny et al. | Nov 2016 | A1 |
20160331532 | Quadri | Nov 2016 | A1 |
20160367360 | Cartledge et al. | Dec 2016 | A1 |
20160367364 | Forrianni et al. | Dec 2016 | A1 |
20170049566 | Zeng et al. | Feb 2017 | A1 |
20170056170 | Zhu et al. | Mar 2017 | A1 |
20170119525 | Rowe et al. | May 2017 | A1 |
20170189174 | Braido et al. | Jul 2017 | A1 |
20170258585 | Marquez et al. | Sep 2017 | A1 |
20170312075 | Fahim et al. | Nov 2017 | A1 |
20180028312 | Thill et al. | Feb 2018 | A1 |
20180228603 | Racchini et al. | Aug 2018 | A1 |
20200188099 | Dvorsky et al. | Jun 2020 | A1 |
20210212819 | Reed et al. | Jul 2021 | A1 |
20210212822 | Reed et al. | Jul 2021 | A1 |
20210212823 | Reed et al. | Jul 2021 | A1 |
Number | Date | Country |
---|---|---|
203736349 | Jul 2014 | CN |
2777618 | Sep 2014 | EP |
2967869 | Jan 2016 | EP |
3697343 | Aug 2020 | EP |
2008-264553 | Nov 2008 | JP |
2015519187 | Jul 2015 | JP |
2001076510 | Oct 2001 | WO |
2003030776 | Apr 2003 | WO |
2015126712 | Aug 2005 | WO |
2007013999 | Feb 2007 | WO |
2011072084 | Jun 2011 | WO |
2011109450 | Sep 2011 | WO |
2014204807 | Dec 2014 | WO |
2015173794 | Nov 2015 | WO |
2017031155 | Feb 2017 | WO |
2019144036 | Jul 2019 | WO |
Entry |
---|
Knee Hiang Lim et al., “Flat or Curved Pericardial Aortic Valve Cusps: A Finite Element Study”, The Journal of Heart Valve Disease Sep. 2004; vol. 13, No. 5, pp. 792-797. |
Search Report and Written Opinion for related PCT Application No. PCT/US2018/050669 dated Nov. 26, 2018 (12 pages). |
Number | Date | Country | |
---|---|---|---|
20190117390 A1 | Apr 2019 | US |
Number | Date | Country | |
---|---|---|---|
62574410 | Oct 2017 | US |